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Abstract
Background: Multiresistant bacteria (MRB) is an increasing problem. Early identification of patients with MRB is
mandatory to avoid transmission and to target the antibiotic treatment. The emergency department (ED) is a key
player in the early identification of patients who are colonized with MRB.
There is currently sparse knowledge of both prevalence and risk factors for colonization with MRSA, ESBL, VRE, CPE
and CD in acutely admitted patients in Western European countries including Denmark. To develop evidence-based
screening tools for identifying carriers of resistant bacteria among acutely admitted patients, systematic collection
of information on risk factors and exposures is required. Since a geographical variation is suspected, it is desirable
to include emergency departments across the country.
The aim of this project is to provide a comprehensive overview of prevalence and risk factors for MRSA, ESBL, VRE,
CPE and CD colonization in patients admitted to Danish ED’s. The objectives are to describe the prevalence and
demography of resistance, co-infections, to identify risk factors for carrier state and to develop and validate a
screening tool for identification of carriers.
Methods: Multicenter descriptive and analytic cross-sectional survey from January–May 2018 of around 10.000
acutely admitted patients > 18 years in 8 EDs for carrier state and risk factors for antibiotic resistant bacteria.
Information about the background and possible risk factors for carrier status together with swabs from the nose,
throat and rectum is collected and analyzed for MRSA, ESBL, VRE, CPE and CD. The prevalence of the resistant
bacteria are calculated at hospital level, regional level and national level and described with relation to residency,
sex, age and risk factors. A screening model for identification of carrier stage of resistant bacteria is developed and
validated.
Discussion: The study will provide the prevalence of colonized patients with resistant bacteria on arrival to the ED
and variation in demographic patterns, and will develop a clinical tool to identify certain risk groups. This will
enable the clinician to target antibiotic treatments and to reduce the in-hospital spreading of resistant bacteria. This
knowledge is important for implementing and evaluating antimicrobial stewardships, screening and infection
control strategies.
Trial registration: Clinicaltrials.gov: NCT03352167 (registration date: 20. November 2017).
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Background
Multiresistant bacteria (MRB) is an increasing problem
in many parts of the world [1]. In Denmark, attention
has been focused in particular to methicillin resistant
Staphylococcus aureus (MRSA), but there has also been
an increase in the prevalence of extended-spectrum
beta-lactamase-producing enterobacteria (ESBL), vanco-
mycin resistant enterococci (VRE) and carbapenem re-
sistant enterobacteria (CPE) [2].
The consequences of the widespread antibiotic use
and thus increasing bacterial resistance to antibiotics
are multiple [3]. Both antibiotic-associated diarrhea
caused by infections with toxin-producing Clostrid-
ium difficile (CD) [4] and infections and spread of
MRB lead to increased healthcare costs, increased
morbidity and mortality [5], and complicate ad-
vanced treatments that depend on effective infection
control, like treatment of malignancies and trans-
plantations [6, 7].
Early identification of patients colonized with resist-
ant bacteria is mandatory to avoid in-hospital trans-
mission and to target the antibiotic treatment to the
individual patient. Antibiotics are used in many areas
of the hospitals, but especially the treatment of
acutely admitted patients often includes an antibiotic
prescription. The emergency departments (ED) are
key players in the in-hospital use of antibiotics and in
the early identification of patients who are colonized
with MRB since the majority of patients are admitted
through these departments.
There is currently very sparse knowledge of both
prevalence and risk factors for colonization with
MRSA, ESBL, VRE, CPE and CD in acutely admitted,
unselected patients in Western Europe countries in-
cluding Denmark. A Danish study has shown that the
prevalence of MRSA in an area with presumed high
numbers of carriers was 0.9% in the emergency de-
partment [8]. The prevalence of the other MRB has
yet to be described at the ED level.
The Danish National Board of Health has published
guidelines for targeted screening for isolation of MRSA,
based on questionnaires concerning exposure factors [9].
This screening is expected to identify only some of the
carriers [8]. In order to clarify the extent of the problem
and prioritize the preventive response to the spread of
MRB, it is crucial to know the prevalence of these bac-
teria in unselected acutely admitted patients to the Da-
nish EDs. To develop evidence-based screening tools for
identifying carriers of resistant bacteria among the
acutely admitted patients, systematic collection of infor-
mation on risk factors and exposures is required. Since
there is a certain geographical variation in prevalence of
carriers, it is desirable to include emergency depart-
ments across the country.
Aims and objectives
The aim of this project is to provide a comprehensive
overview of prevalence and risk factors for MRSA, ESBL,
VRE, CPE and CD colonization in patients admitted to
Danish emergency departments at a national level.
The objectives are:
I) To describe the prevalence of MRSA, ESBL, VRE,
CPE and CD colonization in unselected, acutely
admitted patients and the regional, urban/country
and other demographic variations.
II) To describe the occurrence of simultaneous patient
colonization with two or more resistant bacteria
(MRSA, ESBL, VRE, CPE and CD).
III) To identify risk factors for colonization with
MRSA, ESBL, VRE, CPE and CD
IV) Based on the identified risk factors, to develop
screening tools for identification of carriers.
Methods
Participants, interventions, and outcomes.
Trial design
Multicenter descriptive and analytic cross sectional sur-
vey of acutely admitted patients for risk factors and car-
riage of MRB.
Study setting
The project takes place in emergency departments and
departments of clinical microbiology at the university
hospitals in Odense, Aarhus, Aalborg, and Køge, and the
regional hospitals in Aabenraa, Herning, Hjørring and
Slagelse and covers 4 of the 5 Danish regions, and ap-
proximately 70% of the Danish population.
Eligibility criteria
The inclusion criteria are
– Patients aged 18 years or above.
– Patients present in one of the participating
emergency departments at least 4 h.
– Patients must be mentally competent and able to
consent to participate.
The exclusion criteria are
– Patients who have been admitted for more than 16 h
before enrollment.
– Patients where swabbing in the rectum, nose or
throat is not possible due to anatomic or surgical
reasons.
Interventions
There are no interventions in this study.
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Outcomes
The primary outcome is the presence of MRB (MRSA,
ESBL, VRE, CPE) and CD in patients in the ED,
expressed as prevalence (proportion) in percentage on
admission among the included patients.
The secondary outcomes are the information on ad-
mission concerning risk factors for carriage of antibiotic
resistant bacteria, expressed as the proportion and odds
ratios between patients with and without MRB (Table 1).
Participant timeline
Enrolment to the study commences from January 2018.
Due to local conditions some of the participating depart-
ments will include patients from February 2018. Enroll-
ment continues until the predefined sample size for each
department has been reached, which is estimated to be
no longer than 4 months after the inclusion start in each
department. The last patient is expected to be enrolled
in the end of June 2018.
Sample size
A Danish study showed an MRSA occurrence of 0.9% in
an ED [8]. It is assumed that VRE and CPE have a lower
occurrence and ESBL and CD a higher occurrence [2].
With the funding obtained, 1.325 patients can be in-
cluded per ED, corresponding to 2650 patient in each re-
gion and 10.600 patients in total. The true frequencies of
the prevalence of resistant bacteria with 95% confidence,
based on expected prevalence of resistant bacteria of
0.5%, 1%, 10% and 25% is shown in Table 2 for different
samples sizes (anticipated admission rate of 10.000
patients/year).
For the analysis of risk factors for carrier stage of
resistant bacteria, only calculations at national level will
be performed.
Recruitment
All patients in the ED should be contacted as early as
possible during the enrollment process by a project em-
ployee who informs both verbally and in writing about
the project. If the 4 hour requirement is an obstacle for
receiving the expected number of inclusions, the steer-
ing committee might waive this criterion. The patient is
allowed to have a family member, friend or acquaint-
ance, as a lay representative present at the information.
The project employee will have a healthcare back-
ground (nurse or medical student) and is employed by
the department.
Privacy will be secured during the information and no
treatment must be delayed because of the enrolment.
All patients are offered up to 1 hour’s consideration
time before written consent is obtained. The consent in-
cludes that the project employee is allowed to obtain a
swab from pharynx, nose and rectum, that the microbio-
logical analysis and the exposure information is used for
a scientific purpose, and that information concerning
antibiotic consumption from the patient records is regis-
tered. The patient also receives information about who
he/she can contact afterwards for additional questions.
Data collection methods
Interview
The project staff in the emergency department collects
information about the background and possible risk






-Travel activity last year
-Work/stay at hospital, nursing home,
schools, prison, military, asylum center/
refugee camp, hostel, daycare or war
zone in and outside the Nordic region.
-Signs of infections, shared sports
equipment, tattoos/piercings
-Contact with mink farm, live pigs, cattle or poultry
-Hospitalized for the past six months
-Invasive surgery performed at a foreign clinic/hospital
-Drainage tubes, indwelling catheters, nutrition tubes,
ulcers, abscesses, eczema, chronic skin disorders or IV
drug abuse within the last six months
-Antibiotic treatment within the last 6 months
-Previously carrier of resistant bacteria, household-like
contact with carrier or worked/stayed in places with
known transmission of resistant bacteria
Outcome
variables
-MRSA: methicillin resistant Staphyloccus aureus
-ESBL: extended-spectrum beta-lactamase producing
enterobacteria
-VRE: vancomycin resistant enterococci (VRE)
-CPE: carbapenem resistant enterobacteria
-CD: Clostridium difficile
Table 2 Sample size calculation for prevalence (source
Openepi.com)
Calculations of sample size estimates 95% limits of confidence
sample size (number of patients)






































































Example: at a prevalence of for instance MRSA of 0.5%
the 95% limits of confidence with a sample size of 1.100
patient is +/0.4%, which means that the prevalence with
95% certainty is from 0.1–0.9%.
Assumptions: 10.000 patients pr year, 95% confidence limits
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factors for carrier status through an interview with the
patient. The questions included are prepared on the
basis of the Danish National Board of Health’s guidance
on preventing spreading of MRSA [9].
Collection of swabs
The patient is swabbed in the nose (ESwab (Copan, SSI
Diagnostica, Hillerød, Denmark)), throat (ESwab) and
rectum (FecalSwab (Copan)).
Nasal swabs are obtained by inserting a swab into the
anterior nares and rotating it along the mucous mem-
brane. Throat swabs are collected by rubbing a swab
along the mucosal surfaces of the tonsils and pharynx.
These samples are already collected routinely in
Denmark in selected patients who are screened for
MRSA, according to the guidelines of the National board
of Health.
Rectal swabs are obtained by inserting a swab 1–2 cm.
into the anal canal and rotate it against the mucosal sur-
face a few times. The procedure is comparable to a
temperature measurement in the rectum.
The three swabs are labeled with barcodes containing
information on project department and a unique project
running number. All samples are sent to the regional de-
partment of clinical microbiology using the same trans-
port arrangements as for routine tests.
Microbiological analysis
The collected samples are examined at the Departments
of Clinical Microbiology at Aalborg University Hospital,
Aarhus University Hospital, Odense University Hospital
and Slagelse Hospital. The same method of analysis is
applied to all four departments.
Nose and throat swabs are examined for the presence
of MRSA: An enhancement broth [Tryptic soy broth
supplemented with 2,5% NaCl, 3,5 mg/L cefoxitin and
20 mg/L aztreonam (Herlev Hospital, Herlev, Denmark)]
is inoculated with 100 μL from both ESwab media and
incubated at 35–37 °C for 16–24 h. Subsequently, a se-
lective chromogenic medium [CHROMagar MRSA II
agar (Becton Dickinson, Heidelberg, Germany)] is inocu-
lated with 100 μL of the enhancement broth and incu-
bated for an additional 42–48 h in atmospheric
conditions. Possible isolates of Staphylococcus aureus are
identified by mass spectrometry [(MALDI-TOF-MS:
BioTyper/Bruker (Bruker Daltronics, Bremen, Germany)
or Vitek MS (bioMérieux, Marcy-l’Etoile, France)] and
screened for cefoxitin resistance according to the Euro-
pean Committee on Antimicrobial Susceptibility Testing
(EUCAST, eucast.org) and for the presence of the
mecA-gene by polymerase chain reaction (PCR). mecA--
negative, cefoxitin resistant isolates are examined for the
presence of the mecC-gene.
Rectum swabs are examined for the presence of VRE,
ESBL, CPE and CD. VRE: 100 μL of the FecalSwab
medium are transferred to an enhancement broth [Brain
Heart Infusion Broth supplemented with vancomycin
4 mg/L and 60 mg/L aztreonam (Herlev Hospital)]. The
enhancement broth is incubated at 35–37 °C for 16–
24 h and 100 μL of the broth are subsequently trans-
ferred to a selective chromogenic medium [chromID
VRE Agar (bioMérieux)] and incubated for further 42–
48 h in atmospheric conditions. Possible isolates of En-
terococcus spp are identified by MALDI-TOF-MS and all
confirmed Enterococcus spp isolates are examined for
the presence of the vanA- and vanB-gene by PCR. ESBL,
CPE and CD: Three different selective chomogenic sub-
strates [ESBL: CHROMagar ESBL bi-agar (Becton Dick-
inson), CPE: chromID CARBA SMART agar
(bioMérieux) and CD: chromID C.difficile agar (bioMér-
ieux)] are each inoculated with 100 μL of the FecalSwab
medium and incubated at 35–37 °C under atmospheric
conditions for 18–24 h (ESBL and CPE) or in an anaer-
obic atmosphere for 42–48 h (CD). Suspected isolates of
Enterobacteriaceae (ESBL or CPE) or CD are identified
by MALDI-TOF-MS. Possible ESBL isolates are pheno-
typically characterized according to EUCAST using the
ROSCO Total ESBL Confirm Kit (ROSCO, Taastrup,
Denmark). Possible CPE isolates are screened for mero-
penem susceptibility according to EUCAST and stored
for later genotypic characterization. Possible CD isolates
are examined for the presence of toxin A (tcdA-gene),
toxin B (tcdB-gene) and binary-toxin (cdtA-gene) by
PCR. Binary-toxin positive CD isolates will be examined
for genotypic markers for CD ribotype 027.
All obtained isolates of cefoxitin-resistant Staphylococ-
cus aureus, Enterococcus spp, cefalosporin- and/or
meropenem-resistant Enterobacteriaceae and Clostrid-
ium difficile will be stored at − 80 °C.
Data collection, management, and analysis
Data entry
All patients will be provided with project running num-
ber, which will be used throughout the project in the in-
terviews and processing of microbiological samples to
secure anonymity. An ID file with the project running
number and the personal registration number (PRN)
number will allow tracing the patient information con-
cerning use of antibiotics before the admission in the na-
tional medicine registries, and for returning test answers
to those patients who requested this information.
The answers from the interviews are entered directly
to an electronic questionnaire (SurveyXact®, Rambøll,
Aarhus, Denmark) on tablet PCs used solely for the pro-
ject. Data is transmitted directly to the central secured
data file storage.
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The microbiological samples are analyzed anonym-
ously using project running numbers and microbio-
logical data are recorded in the local laboratory
information system [Aarhus, Odense and Slagelse:
MADS (Aarhus University Hospital, Aarhus, Denmark
[www.madsonline.dk]) and Aalborg: ADBact (Autonik
Ab, Sweden)]. Data is extracted from these databases
after the end of the study to the central database where
the results are merged to the interview information. The
results will not appear in the patients hospital file.
Microbiological test results are merged with the inter-
view data using the project running number and data
from the medicine registries are merged with the data
set by using the PRN number.
After data cleansing and validation the final data file
will be anonymized before data analysis.
Information concerning antibiotic treatment before
the admission will be obtained from National Board of
Health, medicine registries.
The data analyzes are conducted in STATA 14 in co-
operation with a statistician.
The prevalence of the resistant bacteria are calculated
at hospital level, regional level and national level and de-
scribed with relation to residency (region and degree of
urbanization), sex, age and risk factors.
In one part of the national aggregated data set, a
screening model for identification of carrier stage of re-
sistant bacteria is developed, based on the interview and
medicine information. The model is then validated in
another part of the dataset. The model building is based
on the individual resistant bacteria, and includes univari-
ate and multivariate logistic regression. Relevant indica-
tors from well-defined domains are selected, tested for
correlations and interactions as well as goodness of fit of
the final model.
Non-participant analysis is performed. For missing
data multiple imputation is used.
Monitoring
The daily inclusion of participants will be monitored by
the steering committee and the numbers of inclusion
will be instantly available for all the included centers on
a home page.
No interim analysis will be made. The primary analysis
of data will be performed by three members of the steer-
ing committee after the last patient has been included
and all the microbiological analysis finalized. The results
will be discussed and evaluated first in the steering com-
mittee and afterwards with all the included departments.
Protocol amendments
Important protocol modifications like changes in eligibil-
ity criteria or outcome will be communicated to the
relevant parties, i.e. sponsor, trial registry and scientific
ethical committee.
Confidentiality
The test material will be destroyed immediately after the
sample has been analyzed. Bacterial isolates are stored
for further characteristics.
All personal information and project samples are
anonymized throughout the study process using a pro-
ject ID running numbers and the results cannot be seen
in the patient file or made available for the clinical care
providers. The results of the final analysis are expected
to be available only 4–6 months after the index
hospitalization. A key file will be created that connects
the project ID serial number with the patient’s civil
registration number. It allows for further future analyzes
and is necessary for any feedback to the included
patients. The PRN key is registered in the registration
form, which is saved on secured drive.
Access to data
Only the members of the steering committee will have
access to the final trial dataset. Other researches may be
granted access to the anonymized data for analysis on
reasonable request to the corresponding author.
Ancillary and post-trial care
The data files will be handed to the Danish National
Archieves upon completion of the study.
Dissemination policy
The results of the project will be presented in English in
peer-reviewed articles in recognized scientific journals.
A report is also prepared for use by the National Board
of Health, including an overall assessment of the results
and clinical implications, deviations between expected
and actual results and achieved experience in the
project.
The results of the project will also be disseminated
through participation in academic and other confer-
ences, as well as through the printed and electronic
press.
The author panel for both scientific articles and the re-
port to the Health Board will include the steering com-
mittee and one local researcher from each of the
participating emergency departments and clinical micro-
biology departments in accordance with the Vancouver
criteria. No professional writers will be used.
Positive, negative and inconclusive results will be
published.
Discussion
The study will provide the prevalence of colonized
patients with resistant bacteria on arrival to the ED and
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variation in demographic patterns, and will develop a
clinical tool to identify certain risk groups. This will
enable the clinician to target antibiotic treatments and
to reduce the in-hospital spreading of resistant bacteria.
This knowledge is important for implementing and
evaluating antimicrobial stewardships, screening and in-
fection control strategies.
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